Business news and discussion on TalkFuse.
Hims & Hers launches new peptide treatments — while admitting there’s more to learn about efficacy
Hims & Hers has launched five compounded peptide and longevity formulations through its Peptides+ platform, entering a fast-growing market where products are promoted for recovery, fitness and anti-ageing. The company says there is still more to learn about how the peptides should be used and how effective they are, reflecting the limited evidence from robust human trials.
The initial range includes sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine; none of these specific compounded products is approved by the US Food and Drug Administration. Hims said more than 10,000 people joined its early access list within 15 days and plans to add BPC-157 and TB-500, for which most research has been conducted in animals. The rollout follows the easing of federal restrictions on compounding certain unapproved peptides.
In short
- Hims & Hers has introduced five compounded peptide and longevity formulations.
- None of the specific products is FDA-approved.
- The company says more research is needed on effectiveness.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Supporters could argue that offering these formulations through a healthcare platform gives interested adults a more structured route to products already attracting demand, with access to clinician guidance and clearer information about uncertainty. They may also see carefully monitored use and further research as a way to learn where potential benefits exist, while the company’s acknowledgement of limited evidence helps set realistic expectations.
The case against
Critics could argue that selling compounded products with limited robust human evidence risks making uncertain benefits seem established, especially when they are marketed for appealing goals such as recovery and anti-ageing. They may worry that clinician access and consumer demand do not resolve questions about safety, effectiveness or quality, and that expansion could outpace the evidence needed for informed choices.
Explained simply
Hims & Hers is a US telehealth company that sells health products and connects customers with clinicians online. Its new Peptides+ range contains compounded formulations: products prepared by combining ingredients, rather than medicines approved in that form by US regulators.
Peptides are short chains of amino acids, and some are marketed for purposes such as recovery, fitness or ageing. Evidence for many of these uses is limited, particularly from large, well-designed studies in people; research on some planned additions has mainly involved animals.
The launch comes as interest in peptide products grows and rules on compounding some unapproved substances have eased in the US. The distinction between a product being available and its safety or effectiveness being established is central to understanding this market.
Business Companies Health Medicine